Eisai, Daiichi Sankyo In U.S. Battle Over Aricept Generics
This article was originally published in PharmAsia News
Executive Summary
Major Japanese drugmakers Daiichi Sankyo and Eisai are engaged in a battle in the United States over a new market for both companies generic drugs. Daiichi Sankyo's Indian unit, Ranbaxy Laboratories, has six-month U.S. exclusivity for a generic version of Eisai's blockbuster Aricept (donepezil) for treating Alzheimer's disease. To counter that competition, Eisai granted U.S.-based Pfizer's Greenstone unit the right to sell its own generic in exchange for royalty payments. That portion of projected Aricept sales is expected to reach $200 million before late May when Ranbaxy's exclusivity expires. (Click here for more - a subscription may be required
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.